Investigating the Association of Type of Anticoagulation Treatment for Non-valvular Atrial Fibrillation and Risk of Bleeding in England
Status: Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 08 Nov 2018
Price : $35 *
At a glance
- Drugs Apixaban (Primary) ; Warfarin
- Indications Stroke; Thromboembolism
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 29 Oct 2018 Planned End Date changed from 28 Dec 2018 to 29 May 2019.
- 29 Oct 2018 Planned primary completion date changed from 1 Oct 2018 to 4 Mar 2019.
- 30 Apr 2018 New trial record